tirzepatide and bipolar Effects of tirzepatide, a dual GIP GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats Tirzepatide not linked to increased

Some doctors are calling it a statin moment for India

On December 14, 2023, "Science" magazine announced the top ten scientific breakthroughs of the year

The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio, 1.63 [95% CI, 1.172.28]

AstraZeneca - Building a strong obesity and metabolic disease pipeline Amgen - MariTide showing promising obesity treatment potential Roche - Expanding through strategic acquisitions and obesity-focused programs Pfizer - Continuing development efforts in oral obesity medicines Structure Therapeutics - Advancing next-generation oral GLP-1 candidates Viking Therapeutics - Emerging as a major obesity treatment contender Altimmune - Developing innovative metabolic disease therapies Boehringer Ingelheim - Investing in future cardiometabolic opportunities Why is everyone chasing GLP-1

Get consultation

Learn about the temporary and long-term causes of blurred vision in diabetic people and how they're treated.